DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INJECTAFER

« Back to Dashboard

All Clinical Trials for Injectafer

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00994318	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	ICON Clinical Research	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT00994318	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	Luitpold Pharmaceuticals	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT00994318	Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)	Completed	Vifor Inc.	Phase 3	2009-12-01	Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
NCT01950247	Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and to Compare Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs Intravenous Standard of Care for the Treatment of IDA in an Infu	Active, not recruiting	Luitpold Pharmaceuticals	Phase 4	2013-08-01	The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.

Clinical Trial Conditions for Injectafer

Condition Name

Condition Name for Injectafer
Intervention	Trials
Iron-deficiency	3
Iron Deficiency Anemia	3
IDA - Iron Deficiency Anemia	2
Heart Failure	2

Condition MeSH

Condition MeSH for Injectafer
Intervention	Trials
Anemia, Iron-Deficiency	13
Anemia	10
Deficiency Diseases	9
Heart Failure	3

Clinical Trial Locations for Injectafer

Trials by Country

Trials by Country for Injectafer
Location	Trials
United States	45
Poland	3
Germany	1
Russian Federation	1
Czech Republic	1

Trials by US State

Trials by US State for Injectafer
Location	Trials
Texas	6
Florida	4
South Carolina	3
California	3
North Carolina	3

Clinical Trial Progress for Injectafer

Clinical Trial Phase

Clinical Trial Phase for Injectafer
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	8
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Injectafer
Clinical Trial Phase	Trials
Not yet recruiting	6
Recruiting	5
Active, not recruiting	3

Clinical Trial Sponsors for Injectafer

Sponsor Name

Sponsor Name for Injectafer
Sponsor	Trials
Luitpold Pharmaceuticals	10
Vifor Inc.	2
Pharmacosmos A/S	2

Sponsor Type

Sponsor Type for Injectafer
Sponsor	Trials
Industry	16
Other	6
NIH	1